Publications by authors named "M Aubignat"
Objective: Pharmacoresistant tremors, often seen in Parkinson disease and essential tremor, significantly impair patient quality of life. Although deep brain stimulation has been effective, its invasive nature limits its applicability. MR-guided focused ultrasound (MRgFUS) thalamotomy offers a noninvasive alternative, but its cognitive impacts are not fully understood.
View Article and Find Full Text PDFFunctional neurological disorders (FND) represent a major clinical challenge, characterized by neurological symptoms without identifiable organic lesions. Since the initial descriptions by Jean-Martin Charcot in the 19th century, the understanding and management of FND have evolved considerably. This review aims to provide an up-to-date overview of current knowledge on the diagnosis and management of FND, integrating recent advances and multidisciplinary therapeutic approaches.
View Article and Find Full Text PDFArticle Synopsis
- Holmes tremor (HT) is a disorder that causes different types of tremors and can severely affect a patient's daily life; traditional medications often fail to provide consistent relief.
- This study examines the effectiveness of a new surgical technique, called MRI-guided laser interstitial thermal therapy (MRIgLITT), focusing on its impact on tremor severity, quality of life (QOL), and adverse effects in patients with persistent HT.
- Results showed notable improvements in tremor severity and QOL, with patients experiencing a 41% reduction in tremors at 3 months and a 29% reduction at 12 months post-surgery, indicating the potential benefits of this treatment approach.
Background And Objectives: Deep brain stimulation (DBS) is a well-established treatment for Parkinson disease (PD), with programming methods continually evolving. This study aimed to compare the efficacy and patient burden between conventional ring-mode programming (CP-RM) and image-guided volume of tissue activated (IG-VTA) programming for subthalamic nucleus (STN) DBS in PD.
Methods: In this retrospective study, patients with PD who underwent STN-DBS between 2011 and 2014 (CP-RM group) and 2019 and 2021 (IG-VTA group) were evaluated.
Background: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms, primarily because of the impairment of dopaminergic neurons. Long-term use of levodopa, the standard PD treatment, often results in fluctuating therapeutic effects and dyskinesia, necessitating alternative therapies.
Objectives: This review aims to synthesize current insights and clinical experiences with foslevodopa-foscarbidopa, focusing on its pharmacokinetics, efficacy, and safety profile, to evaluate its potential in transforming PD therapy.